Protocol Ledger

NCT07464587 · Phase III · RECRUITING

Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Interventional Phase III clinical trial protocol NCT07464587 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-14 Enrollment: 800 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07464587
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)800 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07464587
Protocol FieldVerified Registry Value
NCT IdentifierNCT07464587
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment800 participants (ESTIMATED)
Registered Start Date2026-04-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07464587
Hospital Research SiteLocationSite Profile
The First Hospital of Lanzhou UniversityLanzhou, ChinaOpen Hospital Dossier ->
Peking University Shenzhen HospitalShenzhen, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI